Ifinatamab Deruxtecan in Patients With Extensive-Stage Small Cell Lung Cancer: Primary Analysis of the Phase II IDeate-Lung01 Trial

I-DXd 12 mg/kg once every 3 weeks showed promising efficacy in patients with previously treated ES-SCLC. The observed safety profile was consistent with previous reports, with no new safety signals identified.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Oncology
Published
2025-10-14
DOI
https://doi.org/10.1200/jco-25-02142
Citations
4
Primary Topic
Lung Cancer Research Studies
Type
article
Field-Weighted Citation Impact
4.18
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Ifinatamab Deruxtecan in Patients With Extensive-Stage Small Cell Lung Cancer: Primary Analysis of the Phase II IDeate-Lung01 Trial

J. Godard, Tetsuya Sakai, Myung‐Ju Ahn, Hidetoshi Hayashi et al.
4 citations
Journal of Clinical Oncology
Lung Cancer Research Studies
4.18
article

Ifinatamab Deruxtecan in Patients With Extensive-Stage Small Cell Lung Cancer: Primary Analysis of the Phase II IDeate-Lung01 Trial

J. Godard, Tetsuya Sakai, Myung‐Ju Ahn, Hidetoshi Hayashi, Yu Jung Kim, Pedro Rocha, Melissa L. Johnson, Charles M. Rudin, Mei Tang, Luis Paz‐Ares, Christine L. Hann, Makoto Nishio, Haichuan Hu, Nicolas M Girard, Jasmeet Singh, Meng Qian
article en
4 citations

Abstract

I-DXd 12 mg/kg once every 3 weeks showed promising efficacy in patients with previously treated ES-SCLC. The observed safety profile was consistent with previous reports, with no new safety signals identified.

Journal of Clinical OncologyVol. 44(4)
Merck & Co., Inc., Rahway, NJ, USA (United States) (US), Memorial Sloan Kettering Cancer Center (US), Daiichi Sankyo (Germany) (DE), Samsung Medical Center (KR), Seoul National University Bundang Hospital (KR), Sarah Cannon (US), Hospital Universitario 12 De Octubre (ES), Vall d'Hebron Hospital Universitari (ES), The Cancer Institute Hospital (JP), National Cancer Center Hospital East (JP), Daiichi Sankyo (United States) (US), Sidney Kimmel Comprehensive Cancer Center (US), Japanese Foundation For Cancer Research (JP), Vall d'Hebron Institute of Oncology (ES), Institut Curie (FR), Sungkyunkwan University (KR), Kindai University (JP)
Openalex Percentile: Top 5%
Lung Cancer Research Studies
4.18
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.